Beyond the Hype: What AI Slop Reveals About the Next Wave of B2B AI
AI slop isn't just a content problem — it's a workflow design problem. We break down the jagged frontier of AI capability and what it means for founders building the next generation of B2B AI tools.
MCED FDA Approval Challenges: Why Multi-Cancer Blood Tests Remain Out-of-Pocket
Why MCED tests haven't achieved FDA approval: Analysis of positive predictive value issues, clinical evidence barriers, and diagnostic costs. Plus market potential insights.
HeartFlow IPO Analysis: Medical AI Company IPO Success Story
HeartFlow's IPO marks the first pure-play medical AI company to reach public markets with 99% AI revenue. Analysis of business model, financials, and roadmap for medical AI startups.
The AI Agent Protocol Wars: How MCP and A2A Are Reshaping Startup Opportunities
AI agents are evolving from solo tools to collaborative teams. Here's how MCP and A2A protocols are enabling startups to build agent businesses without platform dependencies.
